VI-RADS score system – A primer for urologists

Refky Nicola 1, Martina Pecoraro 2, Sara Lucciola 2, Rodolfo Borges dos Reis 3, Yoshifumi Narumi 4, Valeria Panebianco 2, Valdair Francisco Muglia 5

1 Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 2 Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Italy; 3 Departamento de Cirurgia, Divisão de Urologia - Faculdade de Medicina de Ribeirão Preto – USP, Ribeirão Preto, SP, Brasil; 4 Department of Health Care, Kyoto Tachibana, Kyoto, Japan; 5 Departamento de Imagens Médicas, Oncologia e Hematologia - Divisão de Imagem, Faculdade de Medicina de Ribeirão Preto – USP, Ribeirão Preto, SP, Brasil

ABSTRACT

Bladder cancer (BCa) is one of the most common cancers worldwide and is also considered to be one of the most relapsing and aggressive neoplasms. About 30% of patients will present with muscle invasive disease, which is associated with a higher risk for metastatic disease.

The aim of this article is to review the state of art imaging in Radiology, while providing a complete guide to urologists, with case examples, for the rationale of the development of the Vesical Imaging Reporting and Data System (VI-RADS), a scoring system emphasizing a standardized approach to multiparametric Magnetic Resonance Imaging (mpMRI) acquisition, interpretation, and reporting for BCa. Also, we examine relevant external validation studies and the consolidated literature of mpMRI for bladder cancer. In addition, this article discusses some of the potential clinical implications of this scoring system for disease management and follow-up.

ARTICLE INFO

Valdair Francisco Muglia
https://orcid.org/0000-0002-4700-0599

Keywords:
Urinary Bladder Neoplasms; Diffusion Magnetic Resonance Imaging; Genitourinary Tract Anomalies [Supplementary Concept]

Int Braz J Urol. 2022; 48: 609-22

Submitted for publication: August 30, 2021
Accepted after revision: August 31, 2021
Published as Ahead of Print: February 02, 2022

INTRODUCTION

Bladder cancer (BC) is the second common cancer within the genitourinary tract and the ninth most common malignancy in the World. It is even more prevalent within Western Europe (1). As of 2018, the number of global new cases and deaths from bladder cancers were estimated at approximately 550,000 and 200,000, respectively (2).

Smoking is the primary risk factor for bladder cancer and has been associated with over 55% of all cases in the United States (3). In addition, occupational exposure to polycyclic aromatic hydrocarbons and chlorinated hydrocarbons among paint and dye plant workers is the second
most common risk factor (4). Also, the chronic irritation of the bladder mucosa, caused either by chronic urinary tract infections or stones is associated with an increased incidence of squamous cell cancers (5). With bladder cancer, there is a slight male predominance, ranging from 1.3/1.0 in Central Africa up to 4.0/1.0 in Southern Europe (1, 5).

The staging of bladder cancer is of utmost importance. Usually, BC is staged as either non-muscle invasive BC (NMIBC) or muscle invasive BC (MIBC), based on the extension of the tumor invading the bladder wall. The proportion of MIBC, at initial diagnosis, is estimated between 25-30%. The invasion of the muscularis layer of the bladder has tremendous implications in the management and prognosis of the disease.

Despite all advances in the detection of small bladder lesions and carcinoma in situ (CIS), including narrow band imaging, fluorescence cystoscopy, and optical coherence, and the great interest about molecular assays, the chances of progression and recurrence in NMIBC patients are still very high and comparable to those seen at the end of 1990 (6, 7). Some studies have showed that 10-20% of NMIBC patients at one time will eventually progress to MIBC, but roughly 50-70% will recur over time (8). Even when more aggressive management is chosen, the prognosis of BC is poor, with 5-year overall survive of 50% only, and with systemic (metastatic) disease up to 15% (1, 9).

The relevance of BC, however, cannot be estimated only by those numbers. Not only is the mortality rate a significant concern in BC, but also the high rate of recurrence has a great impact on quality of life of a significant portion of patients with BC (8) and the high lifetime treatment-associated costs (10, 11).

The case for an Imaging Stratification Risk Score

Once the diagnosis of BC is made, the status of the bladder wall, according to major International Guidelines (12-14) is defined after tissue sampling performed at transurethral resection of bladder tumor (TURBT).

The need for appropriate staging tool could be scaled when Dutta et al. (15) demonstrated that for the patients who were under staged at initial diagnosis, the 5-year mortality rate was up to 30% higher compared to those correctly staged. One of the main limitations of TURBT for the diagnosis and staging of BC is its low sensitivity for assessment of MIBC (16). As showed, these clinically under staged patients are at higher risk for advance disease progression.

The clinical staging errors, at TURBT procedure, considering only T1 BC lesions, has been described and varies from 24 to 62%. In the series of Fristche et al. (17) and Ark et al. (18), the rate of incorrect staging at first TURBT was quite similar, 49.7% and 48.0%, respectively. In the study of Ark et al., multiple lesions and a history of prior TURBT were considered independent predictors of understaging at radical cystectomy (RC). Currently, en bloc TURBT has been proposed and advocated to reduce recurrence rates and the need for a second TURBT (19).

Besides these relevant implications for patient’s management, TURBT is a quite invasive procedure, although performed on an outpatient basis (12). The risk of bladder perforation is estimated by Herkommer et al. (20) in 1.1 to 5.3% patients. However, this could be underestimated, as demonstrated in a study by Balbay et al. (21), that found bladder perforations occurring in up to 58% of the cases, when using cystograms as the standard of reference.

Based on the lack of reliable molecular assays and the known limitations of TURBT as staging tool, there would be room for a staging technique that could accurately define the status of muscular layer, sparing patients from additional invasive procedures and, at the limit, potentially unnecessary surgery. For a long time, the use of imaging for local staging of BC has been limited to both Computed Tomography, and secondarily to Magnetic Resonance Imaging (MRI) (22-24).

However, based upon enhancement in soft tissue characterization with diffusion-weighted imaging (DWI) and dynamic-contrast enhancement (DCE), the accuracy of the multiparametric MRI for staging BC has significantly increased to greater than 90% (25-27).
Standardization of imaging approach to BC - The VI-RADS initiative

In 2018, a multidisciplinary group of radiologists, urologists, pathologists and radiation oncologist, with an interest in bladder cancer, developed a scoring system (28) aimed to: 1) standardize the protocols for MR imaging of BC; 2) provide a structured reporting system to improve communication between referring physicians and radiologists, and; 3) provide a risk score for muscle layer invasion in BC. This initiative was named VI-RADS (Vesical Imaging-Reporting and Data System), which followed the precursors of “RADS”, the BI-RADS (Breast Imaging-Reporting and Data System) and the PI-RADS (Prostate Imaging-Reporting and Data System).

Briefly, the VI-RADS score system could be divided in three distinct, interconnected steps: patient preparation; exam acquisition protocol and images interpretation.

Patient preparation. Some important details are required in the preparation of patients undergoing a pelvic MRI for BC staging. These steps are all essentials to obtain the best results from the examination (28).

Antispasmodic agents are administered in order to minimize motion and inherent susceptibility artifacts (29). Patients are usually advised to void one to two hours before imaging and, depending on individual tolerance, to drink 0.5 to 1L of water before the examination. Indeed, adequate bladder distension is the major requirement. Ideally, the bladder should not be under or overdistended and a volume of 250 to 300mL is an ideal range for a good examination (30). Rapid sequences or real-time MRI can be used to monitor bladder distension. A good guide is to ensure proper visualization of the vesical dome on sagittal plane: an outward convex contour of the dome usually indicates an adequate distention. Without distention, the bladder wall can appear falsely thicker than usual, which, occasionally, could be misinterpreted as a lesion which can result in over staging (31).

MRI protocol

The VI-RADS is largely based on multiparametric MRI, this multimodal approach was chosen to reduce the risk of error when staging a BC from one single sequence.

The evidence in literature suggests that high-field scanners, 1.5 and 3.0T, can be used indistinctively, as both generate high spatial resolution and signal-to-noise ratio (28, 32). Here, the main recommendation is the use of a phased-array external, surface coil also with at least 16-channels.

The T2-weighted images were named structural category as these images, due to high contrast-resolution and excellent spatial resolution, are well suited for assessing the anatomy of the whole pelvis, including bladder and surrounding structures. These images can be acquired as 2D sequences in three planes (axial, coronal and sagittal) or can be acquired in a single volumetric (3D) acquisition. The choice will be specific for every scanner, as the spatial and contrast resolution may show large variation depending on the vendor and generation of the scanner. The slice thickness should be kept thin, 3.0 to 4.0mm, maximum (33). T2WI is used to assess tumor detection, localization, evaluation of the size and morphology.

Diffusion-weighted images (DWI) is a functional technique based on the movements of water molecules in a given tissue or material (34). DWI has been used in virtually all abdominal examinations due to the significant provided information, particularly in oncological imaging, regardless of the site. It plays a critical role in prostate, liver and bladder cancer imaging (35-37). Although, at first glance, the T2 sequence provides better spatial resolution for assessing the depth of tumor extension, DWI has been proved more accurate for defining muscle layer status. Dynamic contrast enhanced (DCE) MRI is considered the dominant (defining) sequences, when disparities between sequences are found (25, 38). A high B value (800-1000s/mm²) is usually required to visualize BC. Images are obtained in at least the axial plane; however, an additional plane (such as sagittal) is helpful for staging, especially for small lesions (39).

The DCE is the third key component of the VI-RADS and bladder MRI protocol (28). Its acquisition strongly relies on well-defined time points, which improves the differentiation between the inner layer (mucosa + lamina propria) from the muscularis propria (also referred to as detrusor muscle) (40). Although, anatomical evaluation is the major
goal, it can be considered a functional technique, as it reflects vascularity and microvessel permeability and semi-quantitative analysis can be performed from this sequence. The best option is the use of an axial 3D T1-weighted, gradient echo (GRE) sequence with fat-suppression that can be reformatted in other planes, due to high spatial resolution (41). Recently, a prospective study reported similar accuracy of a protocol without intravenous contrast media compared to multiparametric one, for the detection of muscle invasion (42). However, further studies are required for better evaluation of a biparametric approach for BC staging.

The original VI-RADS manuscript provides details of the technical requirements and the acquisition protocol of MRI, along with specific references (28).

**Interpretation and Reporting**

The VI-RADS score has five categories (28), based upon degrees of invasion of the muscularis layer from highly unlikely, category 1, to very likely, category 5 (Table-1).

The initial approach is usually done using T2-weighted images, where the lesions present with intermediate signal, contrasting to the low

| Structured Category (T2) | DCE | DWI |
|-------------------------|-----|-----|
| 1                       |     |     |
| Uninterrupted low SI line representing the integrity of muscularis propia (lesion <1.0 cm; e.g., exophytic tumor with or without stalk or thickened inner layer) | No early enhancement of the muscularis propia (lesions corresponding to SC 1 findings) | Muscularis propia with intermediate continuous SI on DWI (lesion <1cm, hyperintense on DWI and hypointense on ADC, with or without stalk and/or low SI thickened inner layer on DWI) |
| Uninterrupted low SI line representing the integrity of muscularis propia (lesion >1cm; exophytic tumor with stalk and/or high SI thickened inner layer, when present, or sessile/broad-based tumor with high SI thickened inner layer, when present) | No early enhancement of muscularis propia with early enhancement of inner layer (lesions corresponding to SC 2 findings) | Muscularis propia with continuous intermediate SI on DWI (lesion >1cm, hyperintense on DWI and hypointense on ADC, with low SI stalk and/or low SI thickened inner layer on DWI, or broad-based/sessile tumor with low/intermediate SI thickened inner layer on DWI). |
| Lack of category 2 findings with associated presence of an exophytic tumor without stalk, or sessile/broad-based tumor without high SI thickened inner layer but with no clear disruption of low SI muscularis propia | Lack of category 2 findings (lesions corresponding to SC category 3 findings) but with no clear disruption of low SI muscularis propia. | Lack of category 2 findings (lesions corresponding to T2 category 3 findings) but with no clear disruption of low SI muscularis propia. |
| Interruption of low SI line suggesting extension of the intermediate SI tumor tissue to muscularis propia | Tumor early enhancement extends focally to muscularis propia | High SI tumor on DWI and low SI tumor on ADC extending focally to muscularis propia. |
| Extension of intermediate SI tumor to extravesical fat, representing the invasion of the entire bladder wall and extravesical tissues | Tumor early enhancement extends to the entire bladder wall and to extravesical fat | High SI tumor on DWI and low SI tumor on ADC extending to the entire bladder wall and extravesical fat. |
signal of the muscle layer and the high signal of urine (43). This differentiation will be pursued in all sequences of a mpMRI of the bladder (Figure-1). An uninterrupted low signal will be the hallmark of categories 1 and 2, highly predictive of NMIBC, with category 2 reserved for lesions larger than 1.0cm (Figure-2). On the other side, an unequivocally interrupted low signal is the typical finding indicating muscle invasion, reserved for categories 4 and 5 (Figure-3). The latter is assigned when perivesical fat extension and involvement of adjacent structures are present. The category 3 is used when there is absence of category 2 findings, but when no obvious discontinuity of the muscle layer is observed.

The same approach is performed for DWI and DCE images. However, these two categories are the dominant sequences, therefore, in cases where there is discrepancy of findings between structural category (T2 images) and functional sequences (DWI and DCE), these two sequences will prevail, either for downgrading or upgrading the lesion (28). Accordingly, the final classification may be originated from several different combinations of T2, DWI and DCE categories as showed in Figure-4.

The report of any vesical lesion should be done in a semi-structured model (44), following these steps: clinical indication; a brief description of the MRI protocol; findings description including lesion location, morphology, measurements, and signal characteristics, when scoring at T2, DWI and DCE is assigned. The evaluation for transmural extension, adjacent organ invasion (when present), and pelvic lymph nodes and bone status are also performed. Finally, the final category and comments should be provided to summarize the report.

Validation Studies

The VI-RADS score system has been tested in several studies, from all over the World (45-56), either prospective or retrospective in nature. Two major points have been assessed in these initial studies: its reproducibility and its diagnostic accuracy for determining muscle layer invasion (Table-2).

The interobserver agreement for VI-RADS can be considered a major strength for the system. It has been reported in the range of optimal to almost perfect, varying from 0.73 up to 0.92, regardless of the experience of the readers. In a recent meta-analysis of Del Giudice et al. (57), focusing on the reproducibility of VI-RADS, the pooled weighted mean kappa score (κ) was 0.83

**Figure 1** - These pictures illustrate how structural categories (T2 images) of VI-RADS are assigned. The muscularis propria is presented as a thick black layer. The inner layer (urothelium + lamina propria) is a thin white layer. The tumors are shown in grey and the stalk, when present, in black, in continuity with the muscular layer. The inner layer is preserved in categories 1 and 2. In category 3, the inner layer is not seen, but there is no clear sign of muscle invasion. In categories 4 and 5, the tumors have extended to the muscular layer, and in VI-RADS 5, they go beyond, until perivesical fat.
(95% Confidence Interval: 0.78-0.88), in spite of a significant heterogeneity in the studies included in the systematic review. Of importance here is to remember that reproducibility, in a broad sense, may encompass the variations across different scanners and centers, with different levels of experience, which may influence the adoption of a new classification system.

The diagnostic accuracy of VI-RADS has been evaluated in two recent meta-analysis. In the study of Woo et al. (58), six studies, two prospective, were included and the pooled sensitivity was 0.83 (95% confidence interval, 0.70-0.90) and pooled specificity was 0.90 (0.83-0.95), and the accuracy, measured by the area under the ROC curve, was 0.94 (0.91-0.95). Luo et al. (59) also included six studies (five were the same as in the study of Woo et al.), including the same two prospective studies, and pooled sensitivity, specificity, and diagnostic accuracy (again by AUC) were, respectively, 0.90 (0.86-0.94), 0.86 (0.71-0.94), and 0.93 (0.91-0.95) using VI-RADS 3 as the cutoff value for muscle invasion and, 0.77 (0.65-0.86), 0.97 (0.88-0.99), and 0.92 (0.89-0.94) when VI-RADS 4 was the cut off for invasion. In both meta-analysis, there was a significant study heterogeneity. Woo et al. (58) indicated the number of patients in the study, the magnetic field strength of the scanners (3.0 vs. 1.5T), image slice thickness (3 vs. 4mm) in T2 images, and VI-RADS cutoff score, from 3 or 4 as the major source of heterogeneity. In the study of Luo et al. (59), study design (retrospective or prospective) and surgical pattern of standard of reference were the main source of the heterogeneity.

The definition of which score should assumed as indicative of invasion of muscle layer varies, as different scores can be chosen according to

![Image](https://via.placeholder.com/150)
different clinical scenarios. For instance, VI-RADS 3 could be used as the cutoff value when dealing with patients with high pre-test probability of muscle invasion, including, but not limited to, patients with high-grade, recurrent, multiple and or larger lesions (>3.0cm). On the other side, VI-RADS 4 could be defined as the cut off, in clinical settings requiring higher specificity, e.g., more aggressive treatment options are being considered. Both studies showed similar results of a previous meta-analysis, carried out in 2017, before VI-RADS release, including 24 studies, showing pooled sensitivity of 0.92 (95% CI 0.88-0.95) and specificity of 0.87 (95% CI 0.78-0.93). Here, the appeal for the use of VI-RADS relies on the future gains of using a standardized approach for image acquisition and for reporting BC lesions assessed by mpMRI. The potential gain in the reproducibility, as the performance of less skilled readers tend to increase when an established system is used, as demonstrated by the comparison of PI-RADS and Likert scale (60).

Of note, Del Giudice et al. (61) investigated the role of VI-RADS score 5 in predicting time-to-cystectomy (TTC) outcomes. Authors showed, not only that VI-RADS is valid and reliable in differentiating patients with extravesical disease, but also that the identification of a VI-RADS score of 5 implies in a significant delay in TTC, independently from other clinicopathological features. VI-RADS also provided possible alternatives and decision aids in the treatment of BCa during the COVID-19 emergency setting, to minimize potential exposure to the infection by avoiding hospital admissions: patients with NMIBC and preoperative VI-RADS score of 1-2 were directed to appropriate adjuvant intravesical therapy for follow-up, rather than a secondary resection of

![Figure 3 - A 46-year-old, female, complains of frequency, urgency, and severe incontinence. A pelvic sonogram showed moderate to marked left hydronephrosis and asymmetric bladder wall thickening on the top portion of her bladder. A and B) Axial and Coronal T2-weighted MRI of the pelvis demonstrates a 4.4 x 3.6cm mass extending to muscle layer. C) ADC map in the axial plane, and D) T1 post-contrast, also in the axial plane, confirming that mass shows extension into the muscular layer. This was consistent with VI-RADS 4, confirmed after surgery.](image)
Recently, the first multi-institutional, multi-reader study, authored by Ueno et al. (63), who observed moderate to substantial interobserver agreement and a pooled AUC of 0.87 among radiologists of different levels of expertise using VI-RADS, again confirming the existing high reproducibility of score in the “real life” clinical practice (different scans and different reader’s experience).

Perspectives for the use of mpMRI and VI-RADS in Bladder Cancer

The original suitability of VI-RADS system was limited to patients not previously surgically manipulated, to avoid post-procedures changes influencing the final classification (28). This requirement limits the applicability of the score system, as frequently, patients have already submitted to TURBT. Considering the relevance of expanding the use of VI-RADS, new data on this topic is expected to be coming in the near future, with emphasis on the accuracy of MRI and VI-RADS scoring in differentiating inflammatory changes secondary to the surgical procedure from malignant findings (64-67).

A second issue for potential VI-RADS updating is the incorporation of associated findings. Currently, there is no place for citing these features, some of them with a potential to change management of the lesion, for instance, hydronephrosis (68).

Another potential use of mpMRI and VI-RADS is to stratify patients diagnosed with high-risk NMIBC at first TURBT (69, 70). The risk of muscle layer invasion at radical cystectomy, in these patients is estimated in about 30% (71, 72). In this setting, the use of VI-RADS for risk stratification and discrimination of those who should undergo secondary tumor resection and those who can be spared might be assessed in the near future. A trial assessing the value of mpMRI in this clinical setting was initiated in the United Kingdom (73), where the “Bladder-Path” study was designed to divide patients with confirmed BC after first TURBT, into a group with probable NMIBC, receiving current standard approach, from another group composed of patients with risk factors for MIBC, who will proceed to mpMR imaging for differentiation between MIBC and NMIBC.

With regards to the high rate of recurrence for BC, the post-treatment surveillance is another

Figure 4 - The decision algorithm for VI-RADS. When all categories are coincident, the final score is directly assigned. When classification in different sequences is discordant, DCE, and DWI are the dominant sequences and will prevail for the final classification. As seen in figure 4, DCE and DWI can upgrade or downgrade the initial classification found on T2 images.
Table 2 - Main validation studies published until March 2021.

| Study/Year       | Country | Study Type     | Nature     | # of Patients | Interreader Agreement | Sensitivity | Specificity | Accuracy | Standard of Reference |
|------------------|---------|----------------|------------|---------------|------------------------|-------------|-------------|----------|-----------------------|
| Ueno et al. 2019 | Japan   | Original Research | Retrospective | 74            | ICC=0.85               | 0.76 (Cat. ≥4) | 0.93 (Cat. ≥4) | 90       | TURB                  |
| Barchetti et al. | Italy   | Original Research | Retrospective | 75            | K=0.73                 | 0.82 - 91 (Cat. ≥3) | 0.85 - 0.89 (Cat. ≥3) | 0.87 - 0.93 | TURB                  |
| Wang et al. 2019 | China   | Original Research | Retrospective | 340           | K=0.92                 | 0.87 (Cat. ≥3) | 0.97 (Cat. ≥4) | 0.94     | TURB, Cystectomy       |
| Makboul et al. 2019 | Egypt   | Original Research | Prospective | 50            | K=0.87                 | 0.78 (Cat. ≥3) | 0.88 (Cat. ≥3) | 0.83     | TURB                  |
| Kim et al. 2019  | South Korea | Original Research | Retrospective | 297           | K=0.89 (T2) K=0.82 (DWI) K=0.85 (DCE) | 0.91 (Cat. ≥4) | 0.76 (Cat. ≥4) | 9.44 (Cat. ≥3) | N/A       |
| Del Giudice et al. 2019 | Italy   | Original Research | Prospective | 231           | K=0.92                 | 0.92 (Cat. ≥3) | 0.91 (Cat. ≥3) | 0.94     | TURB, Cystectomy       |
| Hong et al. 2020 | South Korea | Original Research | Retrospective | 66            | K=0.97                 | 0.90 (Cat. ≥3) | 1.0 (Cat. ≥3) | 0.95     | TURB, Cystectomy       |
| Marchioni et al. 2020 | Italy   | Original Research | Prospective | 38            | K=0.76                 | 0.86 (Cat. ≥4) | 0.87 (Cat. ≥4) | 0.90     | TURB                  |
| Liu et al. 2020  | China   | Original Research | Retrospective | 126           | N/A                    | 0.94 (Cat. ≥4) | 0.92 (Cat. ≥4) | 0.90     | TURB, Cystectomy       |
| Wang et al. 2020 | China   | Original Research | Retrospective | 220           | N/A                    | 0.92 (Cat. ≥4) | 0.95 (Cat. ≥4) | 0.96     | TURB, Cystectomy       |
| Sakamoto et al. 2020 | Japan   | Original Research | Retrospective | 176           | K=0.43                 | 0.63 (Cat. ≥4) | 0.78 (Cat. ≥3) | 0.86     | TURB                  |
| Metwally et al. 2021 | Egypt   | Original Research | Prospective | 331           | K=0.93                 | 0.84 (Cat. ≥4) | 0.90 (Cat. ≥4) | 0.94     | TURB                  |
| Woo et al. 2020  | USA     | Meta-analysis    |            | 1770 (6 studies) | K=0.81 - 0.92 ICC=0.85 | 0.83 | 0.90 | 0.94 | TURB, Cystectomy |
| Luo et al. 2020  | China   | Meta-analysis    |            | 1064 (6 studies) | N/A                    | 0.90 | 0.86 | 0.93 | TURB, Cystectomy |

*number of citation in the text.
N/A = not available.
TURB = Transurethral resection of bladder.
potential use of mpMRI (72). Although, cystoscopy is the gold-standard in the follow-up of these patients, a non-invasive tool could be helpful, especially when a local recurrence is suspected. In follow-up period, inflammatory changes after a TURBT may persist for up to 24 months (66) and could be misinterpreted, mostly within 2 weeks from the procedure, as residual or recurrent disease especially on T2-weighted images. Nonetheless, DCE and especially DWI are crucial for the correct interpretation.

The medical treatment for NMIBC and MIBC includes chemotherapy, immune checkpoint inhibitors and Bacillus Calmette-Guerin (BCG) intravesical instillations (74). However, considering the limitations of applying solid tumors response criteria in the bladder to evaluate tumor burden before and after medical treatment, mpMRI has been useful in the assessment of these patients as demonstrated by a marked increase in the ADC values with complete response after neoadjuvant chemotherapy (75-77). Also, considering the response to immunotherapy, Necchi et al. (78) demonstrated the promising role of MRI in the evaluation of response to therapy before and after immunotherapy. However, it did so apply a dichotomic method, which implied fewer promising outcomes from the combined complete/partial responder’s assessment (i.e., pT≤1). Instead, the use of a five-scale assessment score for response to system therapy might provide a model to define the complete spectrum of pathological treatment response among MIBC patients ultimately undergoing RC.

CONCLUSIONS

The technological innovation of MR imaging has advanced the assessment of bladder cancer. These ongoing developments have yet to be better defined but arguably have the potential to change how BC is staged and monitored. In the future, MR findings can be incorporated to increase the accuracy of the traditional prediction models as the EORTC, CUETO, and EAU risk stratification. The use and implication of VI-RADS will improve the communication in the diagnosis, staging and surveillance of patients with bladder cancer.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Zang Y, Li X, Cheng Y, Qi F, Yang N. An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study. Ann Transl Med. 2020; 8:1587.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424. Erratum in: CA Cancer J Clin. 2020; 70:313.
3. Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011; 185:1631-6.
4. Al-Husseini MJ, Kunbaz A, Saad AM, Santos JV, Salahia S, Iqbal M, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019; 19:46.
5. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63:234-41.
6. Soukup V, apoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol. 2017; 72:801-13.
7. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017; 198:552-9. Erratum in: J Urol. 2017; 198:1175.
8. Canter DJ, Revenig LM, Smith ZL, Dobbs RW, Malkowicz SB, Issa MM, et al. Re-examination of the natural history of high-grade T1 bladder cancer using a large contemporary cohort. Int Braz J Urol. 2014; 40:172-8.
9. Maisch P, Lunger L, Düwel C, Schmid SC, Horn T, Gschwend JE, et al. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer. Urol Oncol. 2021; 39:368.e11-368.e17.
10. Mossanen M, Wang Y, Szymaniak J, Tan WS, Huynh MJ, Preston MA, et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019; 37:2059-65.

11. Korkes F, Maluf F. Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies. Int Braz J Urol. 2021; 47:443-7.

12. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017; 71:462-75.

13. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196:1021-9.

14. https://auau.auanet.org/sites/default/files/US2018%20Lesson%2029.pdf. From www.aua.net. Accessed Jan 4th, 2021.

15. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001; 166:490-3.

16. Matulewicz RS, Frainey BT, Oberlin DT, Meeks JJ. High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy. J Natl Compr Canc Netw. 2016; 14:1403-11.

17. Fritzsche HM, Burger M, Svatuk RS, Jeldes C, Karakiewicz PI, Novara G, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010; 57:300-9. Erratum in: Eur Urol. 2015; 68:171.

18. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014; 113:894-9.

19. Bangash M, Ather MH, Khan N, Mohammad S, Uddin Z. Comparison Of Recurrence Rate Between “EN BLOC” Resection Of Bladder Tumour And Conventional Technique For Non-Muscle Invasive Bladder Cancer. J Ayub Med Coll Abbottabad. 2020; 32:435-40.

20. Hermann K, Hofer C, Gschwend JE, Kron M, Treiber U. Gender and body mass index as risk factors for bladder perforation during primary transurethral resection of bladder tumors. J Urol. 2012; 187:1566-70.

21. Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koç A, Akbulut Z. The actual incidence of bladder perforation following transurethral bladder surgery. J Urol. 2005; 174:2260-2.

22. Persad R, Kabala J, Gillatt D, Penny B, Gingell JC, Smith PJ. Magnetic resonance imaging in the staging of bladder cancer. Br J Urol. 1993; 71:566-73.

23. Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology. 2004; 231:725-31.

24. Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology, 1994; 193:239-45.

25. Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, et al. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009; 251:112-21.

26. Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013; 82:2161-8.

27. Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017; 27:3759-66.

28. Panebianco V, Narumi Y, Altun E, Bochner BH, Elstathiu JA, Hafeez S, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018; 74:294-306.

29. Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R. The value of hyoscine butylbromide in pelvic MRI. Clin Radiol. 2007; 62:1087-93.

30. Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol. 2012; 61:326-40.

31. Pecoraro M, Takeuchi M, Vargas HA, Muglia VF, Cipollari S, Catalano C, et al. Overview of VI-RADS in Bladder Cancer. AJR Am J Roentgenol. 2020; 214:1259-68.
32. Zhou G, Chen X, Zhang J, Zhu J, Zong G, Wang Z. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol. 2014; 83:2013-8.
33. Panebianco V, Barchetti F, de Haas RJ, Pearson RA, Kennish SJ, Giannarini G, et al. Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. Eur Urol Focus. 2016; 2:113-21.
34. Baliyan V, Das CJ, Sharma S, Gupta AK. Diffusion-weighted imaging in urinary tract lesions. Clin Radiol. 2014; 69:773-82.
35. Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, et al. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology. 2019; 292:464-74.
36. [No Authors]. Liver Reporting & Data System (LI-RADS). [Internet]. Available at. <https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS> Accessed on Jan 4th, 2021.
37. El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int. 2012; 110(11 Pt B):E622-7.
38. Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017; 27:3759-66.
39. Takeuchi M, Sasaki S, Naiki T, Kawai N, Kohri K, Hara M, et al. MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging. 2013; 38:1299-309.
40. Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology. 1998; 207:791-7.
41. Panebianco V, Pecoraro M, Del Giudice F, Takeuchi M, Muglia VF, Messina E, et al. VI-RADS for Bladder Cancer: Current Applications and Future Developments. J Magn Reson Imaging. 2022;55:23-36.
42. Delli Pizzi A, Mastrodicasa D, Marchioni M, Primiceri G, Di Fabio F, Cianci R, et al. Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. Eur Radiol. 2021; 31:3874-83.
43. Caglic I, Panebianco V, Vargas HA, Bura V, Woo S, Pecoraro M, et al. MRI of Bladder Cancer: Local and Nodal Staging. J Magn Reson Imaging. 2020; 52:649-67.
44. Buckley BW, Daly L, Allen GN, Ridge CA. Recall of structured radiology reports is significantly superior to that of unstructured reports. Br J Radiol. 2018; 91:20170670.
45. Ueno Y, Takeuchi M, Tamada T, Sofue K, Takahashi S, Kamishima Y, et al. Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study. Eur Urol. 2019; 76:54-6.
46. Barchetti G, Simone G, Ceravolo I, Salvo V, Campa R, Del Giudice F, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol. 2019; 29:5498-506.
47. Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019; 291:668-74.
48. Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019; 92:20190401.
49. Kim SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY). 2020; 45:491-8.
50. Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2020; 77:101-9.
51. Hong SB, Lee NK, Kim S, Son IW, Ha HK, Ku JY, et al. Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. J Magn Reson Imaging. 2020; 52:1249-56.
52. Marchioni M, Primiceri G, Delli Pizzi A, Basilico R, Berardinelli F, Mincuzzi E, et al. Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study. Clin Genitourin Cancer. 2020; 18:409-415.e1.
53. Liu S, Xu F, Xu T, Yan Y, Yao X, Tang G. Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl Androl Urol. 2020; 9:445-51.
54. Wang Z, Shang Y, Luan T, Duan Y, Wang J, Wang H, et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging. 2020; 20:26.
55. Sakamoto k, Ito M, Nakanishi Y, Kataoka M. Prediction of muscle invasive bladder cancer using the Vesical Imaging-Reporting and Data System and apparent diffusion coefficient values (VI-RADS/ADC). European Urology Supplements 2019, 18:e242-e243.
56. Metwally MI, Zeed NA, Hamed EM, Elshetry ASF, Elfwakhry RM, Alaa Eldin AM, et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol. 2021; 31:6949-61.
57. Del Giudice F, Pecoraro M, Vargas HA, Cipollari S, De Berardinis E, Bicchetti M, et al. Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers (Basel). 2020; 12:2994.
58. Woo S, Panebianco V, Narumi Y, Del Giudice F, Muggia VF, Takeuchi M, et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020; 3:306-315. Erratum in: Eur Urol Oncol. 2020; 3:811.
59. Luo C, Huang B, Wu Y, Chen J, Chen L. Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur Radiol. 2020; 30:4606-14.
60. Catala V, Barcina MJM, Mayordomo O, et al. Characterization of prostate lesions as benign or malignant by multiparametric 3 T MR imaging: comparison of Likert score to the Prostate Imaging Reporting and Data System 2 version Cancer Imaging. 2020;20:26.
61. Del Giudice F, Leonardo C, Simone G, Pecoraro M, De Berardinis E, Cipollari S, et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020; 126:610-9.
62. Panebianco V, Del Giudice F, Leonardo C, Sciarrara A, Catalano C, Catto JWF. VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. Eur Urol. 2020; 78:e18-e20.
63. Ueno Y, Tamada T, Takeuchi M, Sofue K, Takahashi S, Kamishima Y, et al. VI-RADS: Multinstitutional Multireader Diagnostic Accuracy and Interobserver Agreement Study. AJR Am J Roentgenol. 2021; 216:1257-66.
64. El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int. 2012; 110(11 Pt B):E622-7.
65. Barentsz JO, Jager GJ, van Vierzen PB, Witjes JA, Strijk SP, Peters H, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology. 1996; 201:185-93.
66. Johnson RJ, Carrington BM, Jenkins JP, Barnard RJ, Read G, Isherwood I. Accuracy in staging carcinoma of the bladder by magnetic resonance imaging. Clin Radiol. 1990; 41:258-63.
67. Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging. 2014; 39:135-41.
68. Xiao GQ, Rashid H. Bladder Neck Urothelial Carcinoma: A Urinary Bladder Subsite Carcinoma With Distinct Clinicopathology. Int J Surg Pathol. 2015; 23:517-23.
69. van der Heijden AG, Witjes JA. Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery? Eur Urol Oncol. 2020; 3:316-7.
70. Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol. 2020; 46:169-84.
71. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008; 102(9 Pt B):1242-6.
72. Sim KC, Sung DJ. Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer. Transl Androl Urol. 2020; 9:2890-907.
73. [No Authors]. BladderPath:Image Directed Redesign of Bladder Cancer Treatment Pathway. [Internet]. Available at. <https://www.birmingham.ac.uk/research/crctu/trials/Bladder-Path/index.aspx>. Accessed Jan 5th, 2021.
74. Grisay G, Pierrard J, Confente C, Seront E. Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Curr Treat Options Oncol. 2020; 22:7.

75. Yoshida S, Koga F, Kobayashi S, Tanaka H, Satoh S, Fuji Y, et al. Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. World J Radiol. 2014; 6:344-54.

76. Nguyen HT, Mortazavi A, Pohar KS, Zynger DL, Wei L, Shah ZK, et al. Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy? Bladder Cancer. 2017; 3:237-44.

77. Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2012; 83:e21-7.

78. Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2020; 77:636-43.

Correspondence address:
Valdair F. Muglia, MD
Hospital de Clinicas de Ribeirão Preto
Avenida Bandeirantes, 3900,
Campus Universitário Monte Alegre,
Ribeirão Preto, SP, 14049-900, Brasil
E-mail: fmuglia@fmrp.usp.br